Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8236538 | International Journal of Radiation Oncology*Biology*Physics | 2009 | 10 Pages |
Abstract
Use of RT alone with doses of less than 40 Gy did not result in clinically significant hearing loss. High-frequency SNHL was profoundly damaged in patients who received concomitant cisplatin when doses of 100 mg/m2 were used. The threshold cochlear dose for hearing loss with cisplatin-based chemotherapy and RT was predicted to be 10 Gy. The inner ear radiation dose constraints and cisplatin dose intensity should be considered in the treatment of advanced head-and-neck cancer.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Ying J. M.D., Jonathan D. M.D., Ph.D., Aniko Ph.D., Brandon G. M.D., Dennis C. M.D., Ph.D.,